Craig M. Rush
YOU?
Author Swipe
View article: Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer
Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer Open
Estrogen receptor alpha (ER) is an established oncogenic transcription factor in breast and endometrial cancer; however, more is known about the mechanisms controlling ER behavior in breast cancer, and therapies targeting ER have been much…
View article: Supplementary Materials and Methods from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Supplementary Materials and Methods from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Open
Supplementary Materials and Methods
View article: Supplemental Figure 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Supplemental Figure 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Open
Comparison of mutant ER regulated genes and genes regulated by sustained estrogen signaling
View article: Supplemental Figure 6 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Supplemental Figure 6 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Open
Identification of novel therapeutic targets in ER active and mutant endometrial cancer
View article: Supplemental Figure 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Supplemental Figure 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Open
Validation and gene expression analysis of ER mutant models
View article: Supplemental Figure 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Supplemental Figure 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Open
ER binding is altered by the Y537S and D538G mutations
View article: Supplemental Table 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Supplemental Table 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Open
Differentially expressed genes from in vivo RNA-seq experiments
View article: Supplemental Figure 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Supplemental Figure 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Open
ER mutants do not affect proliferation, but down-regulate proteins associated with movement and impact migration
View article: Supplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Supplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Open
Differentially expressed genes from in vitro RNA-seq experiments
View article: Supplemental Table 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Supplemental Table 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Open
Mutant ESR1 generation: gBlock used for template amplification
View article: Supplemental Figure 5 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Supplemental Figure 5 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Open
ER-Y537S and ER-D538G mutants drive proliferative gene expression signatures in vivo
View article: Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Open
Overlap between prolonged E2 treatment and differentially expressed genes in vitro
View article: Progesterone and Estrogen Signaling Impact Each Other’s Transcriptional Activity in Endometrial Cancer
Progesterone and Estrogen Signaling Impact Each Other’s Transcriptional Activity in Endometrial Cancer Open
Text Endometrial cancer (EC) is the most common gynecologic cancer in the United States and is increasing in incidence. The most common form of EC is hormonally driven by excess estrogens unopposed by progesterone. Despite the use of proge…
View article: ARID1A Suppresses Proliferative Signaling Driven by Estrogen Receptor alpha in Endometrial Cancer
ARID1A Suppresses Proliferative Signaling Driven by Estrogen Receptor alpha in Endometrial Cancer Open
Text Endometrial cancer (EC) is the most common gynecologic cancer in the United States and is now the 4th most common cancer in women. With rising incidence and declining 5-year survival rates over the last several decades, EC is now resp…
View article: Supplemental Table 3 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Table 3 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
Differentially expressed genes from in vivo RNA-seq experiments
View article: Supplemental Figure 4 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Figure 4 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
ER mutants do not affect proliferation, but down-regulate proteins associated with movement and impact migration
View article: Supplemental Figure 2 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Figure 2 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
Comparison of mutant ER regulated genes and genes regulated by sustained estrogen signaling
View article: Supplementary Materials and Methods from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplementary Materials and Methods from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
Supplementary Materials and Methods
View article: Supplemental Figure 3 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Figure 3 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
ER binding is altered by the Y537S and D538G mutations
View article: Supplemental Figure 6 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Figure 6 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
Identification of novel therapeutic targets in ER active and mutant endometrial cancer
View article: Supplemental Figure 3 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Figure 3 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
ER binding is altered by the Y537S and D538G mutations
View article: Supplemental Table 3 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Table 3 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
Differentially expressed genes from in vivo RNA-seq experiments
View article: Supplemental Figure 4 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Figure 4 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
ER mutants do not affect proliferation, but down-regulate proteins associated with movement and impact migration
View article: Supplemental Table 2 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Table 2 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
Overlap between prolonged E2 treatment and differentially expressed genes in vitro
View article: Supplemental Figure 5 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Figure 5 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
ER-Y537S and ER-D538G mutants drive proliferative gene expression signatures in vivo
View article: Supplemental Figure 1 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Figure 1 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
Validation and gene expression analysis of ER mutant models
View article: Supplemental Table 4 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Table 4 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
Mutant ESR1 generation: gBlock used for template amplification
View article: Supplemental Table 1 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Table 1 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
Differentially expressed genes from in vitro RNA-seq experiments
View article: Supplemental Table 2 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplemental Table 2 from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
Overlap between prolonged E2 treatment and differentially expressed genes in vitro
View article: Supplementary Materials and Methods from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Supplementary Materials and Methods from Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer Open
Supplementary Materials and Methods